The American pharmaceutical company Novavax has postponed plans to apply for the approval of its corona vaccine until the third quarter.
Novavax announced the delay on Monday, less than a week after the global vaccine program Covax entered into an agreement to purchase 350 million doses of the corona vaccine.
At the time, it was said that the doses, subject to approval by supervisory authorities, would be delivered from the third quarter of 2021 onwards in 2022.
On Monday, the company stated that it hopes to apply for approval for the vaccine in the US and Europe in the third quarter.
Novavax’s vaccine requires two doses for full effect and can be stored in regular refrigerators. Tests show that the vaccine is 100% effective in preventing serious COVID-19 disease and provides 89.7% protection against all variants of the disease.
Covax was formed to help developing countries also receive corona vaccines. The program is led by the World Health Organization (WHO), the vaccine alliance Gavi, and an organization working on innovation in the pandemic field.
Norway has contributed NOK 1.3 billion to the Covax collaboration effort.
The news on Monday about the delay sent the value of the company’s shares down 12%. In total, Novavax has signed a letter of intent with Covax to deliver 1.1 billion vaccine doses.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at firstname.lastname@example.org